Evidence map›Paper›PMID 40372064›Full record

ArticleMicrobiology spectrum2025

Investigating the profile of patients with idiopathic inflammatory myopathies in the post-COVID-19 period.

Lu Cheng, Yan-Hong Li, Yin-Lan Wu, Yu-Bin Luo, Yu Zhou, Tong Ye, Xiu-Ping Liang, Tong Wu, De-Ying Huang, Jing Zhao and 3 more

Abstract read
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lu Cheng *Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0001-5875-0339
Yan-Hong Li *Department of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Yin-Lan WuDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Yu-Bin LuoDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Yu ZhouDepartment of Respiratory and Critical Care Medicine, Chengdu First People's Hospital, Chengdu, China.
Tong YeDepartment of Basic Medicine, Tianfu College, Southwestern University of Finance and Economics, Chengdu, China.
Xiu-Ping LiangDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Tong WuDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
De-Ying HuangDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Jing ZhaoDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Yi LiuDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.
Zong-An LiangDepartment of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-8358-9177
Chun-Yu TanDepartment of Rheumatology and Immunology, Laboratory of Rheumatology and Immunology West China Hospital, Sichuan University, Chengdu, China.ORCID 0000-0002-3947-9499

Funding

International S and T Cooperation Program of Sichuan Province 2023YFH0081Sichuan Association for Science and Technology 2020YFS0005
6 · The paper itself

Abstract

The 2019 coronavirus disease (COVID-19) pandemic has changed the characteristics of many diseases. It remains unclear whether idiopathic inflammatory myopathies (IIMs) exhibit distinct phenotypes in the context of COVID-19. This retrospective study analyzed patients with IIMs admitted to West China Hospital from January 2022 to December 2023. Among them, 171 had a history of COVID-19 (prior COVID-19 [PC]), while 121 did not (no prior COVID-19 [NPC]). Medical histories, lab tests, and echocardiography data were compared. The PC group exhibited a greater incidence of cardiac damage, including a greater proportion of cardiac injury ( IMPORTANCE: This study systematically analyzed the clinical features, laboratory test results, and echocardiographic findings of patients with IIMs, comparing those with and without a history of COVID-19 infection. The analysis revealed significant alterations in the clinical manifestations of IIM patients after COVID-19, particularly in relation to cardiac involvement. Our findings highlight the crucial importance for clinicians to maintain vigilance concerning the potential long-term cardiovascular sequelae associated with IIMs in post-COVID-19 patients.

Indexed as

COVID-19MyositisAdultAgedChinaEchocardiographyFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainRetrospective StudiesSARS-CoV-2Natriuretic Peptide, BrainCOVID-19idiopathic inflammatory myopathy (IIM)myocardial damagepost-COVID-19SARS-CoV-2

Identifiers

PMID40372064
PMCPMC12131821

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.